News October 2021

Reapplix Receives U.S. Coding And Reimbursement Details For 3C Patch for DFUs

Reapplix recently announced that coding details and reimbursement level have been set for its autologous platelet-rich plasma product 3C Patch^® for the treatment of chronic non-healing diabetic wounds for up to 20 weeks.

The company notes the completion of the transmittal follows the announcement of National Coverage Determination (NCD) in April 2021. Under the established coding regimen, Reapplix says the 3C Patch application is reimbursed at a national average reimbursement rate of $1,715 per treatment, increasing to $1,759 from January 1, 2022.

Following the issue of a change request by the Centers for Medicare and Medicaid Services (CMS), the Medicare Administrative Contractors (MACs) now have until November 9, 2021 to update their systems enabling electronic handling of reimbursement claims from health care providers.

The 3C Patch draws on the body’s capacity to aid its own healing process and is an advanced biologic autologous cell therapy targeting hard-to-heal diabetic foot ulcers (DFUs), according to the company. The 3C Patch System uses the patient's own blood, without adding any reagents or additives, to produce a three-layered patch containing leukocyte cells, platelets and growth factors, enabling a more optimal healing environment, conducive in establishing a normal wound healing process. The company cites a randomized controlled trial published in The Lancet Diabetes & Endocrinology in 2018 that highlights the product’s efficacy.

Click here for more info.

MolecuLight i:X^® Receives FDA 510(k) Clearance for Wounds Likely to Contain Pseudomonas aeruginosa

MolecuLight Inc. recently announced it has received FDA 510(k) clearance for the detection of wounds containing clinically significant levels (>10⁴ CFU/g) of Pseudomonas aeruginosa for the previously cleared MolecuLight i:X imaging device.

As the company notes, the i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria. This new FDA clearance supports the ability of the i:X device to increase the clinician’s ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal. The augmented labeling is based on a detailed retrospective statistical analysis of over 350 patients, according to MolecuLight.
 
As MolecuLight says, the i:X is the only imaging device that provides real-time information on whether a wound is likely to contain elevated levels of P aeruginosa (>10⁴ CFU/g).

Click here for more info.

MedBridge Partners With KanTime Healthcare Software to Help Home Care Agencies Improve Both Quality of Care and Affordability

MedBridge and KanTime Healthcare Software are partnering to help home care and hospice agencies deliver higher quality of care by engaging staff and patients with evidence-based education on an innovative technology platform.

KanTime Healthcare Software provides cloud-based enterprise software to home health and hospice agencies to help improve clinical compliance, increase operational efficiency, and achieve financial success. MedBridge develops best-in-class health care education and patient engagement solutions that allow organizations to significantly improve staff retention, quality of care, and margins.

As the home health industry continues to face challenges around staff retention, agencies are searching for ways to better attract, onboard, and engage staff. MedBridge helps agencies create targeted onboarding programs at scale to put confident and competent staff in the field sooner, and allows organizations to build ongoing development programs for advanced specialization, as well as remediation tracks to address gaps in performance, according to a press release. MedBridge's virtual platform helps agencies elevate quality of care at a lower cost by helping them more effectively manage their patient populations.

Click here for more info on KanTime Healthcare Software.

Click here for more info on MedBridge.